Amgen Set To Face Off With Hospira In Biosimilar IP Trial
Pharmaceutical companies Amgen Inc. and Hospira Inc. are set to square off later this month in a patent infringement trial centering on Hospira's efforts to produce a biosimilar version of Amgen's...To view the full article, register now.
Already a subscriber? Click here to view full article